AP NEWS
Press release content from Business Wire. The AP news staff was not involved in its creation.
PRESS RELEASE: Paid content from Business Wire
Press release content from Business Wire. The AP news staff was not involved in its creation.

Castle Biosciences to Present at Upcoming Investor Conferences

November 20, 2019

FRIENDSWOOD, Texas--(BUSINESS WIRE)--Nov 20, 2019--

Castle Biosciences, Inc. (Nasdaq: CSTL), a skin cancer diagnostics company providing personalized genomic information to improve cancer treatment decisions, today announced that Derek Maetzold, president and chief executive officer, will present at the following upcoming investor conferences:

Live audio webcasts of the company’s presentations will be available by visiting Castle Biosciences’ website at https://ir.castlebiosciences.com/news-events/events-presentations. A replay of the webcast will be available for two weeks following the conclusion of the live broadcast.

About Castle Biosciences

Castle Biosciences (Nasdaq: CSTL) is a commercial-stage dermatologic cancer company focused on providing physicians and their patients with personalized, clinically actionable genomic information to make more accurate treatment decisions. The Company currently offers tests for patients with cutaneous melanoma (DecisionDx ® -Melanoma, DecisionDx ® -CM Seq; www.SkinMelanoma.com ) and uveal melanoma (DecisionDx ® -UM, DecisionDx ® -PRAME and DecisionDx ® -UM Seq; www.MyUvealMelanoma.com ), with products in development for other underserved cancers, the two most advanced of which are focused on patients with cutaneous squamous cell carcinoma, and patients who have a difficult-to-diagnose pigmented lesion. Castle Biosciences is based in Friendswood, Texas (Houston), and has laboratory operations in Phoenix, Arizona. For more information, visit www.CastleBiosciences.com.

DecisionDx-Melanoma, DecisionDx-CM Seq, DecisionDx-UM, DecisionDx-PRAME and DecisionDx-UM Seq are trademarks of Castle Biosciences, Inc.

View source version on businesswire.com:https://www.businesswire.com/news/home/20191120005028/en/

CONTACT: Derek Maetzold, President and CEO

866-788-9007

IR@castlebiosciences.com

KEYWORD: UNITED STATES NORTH AMERICA TEXAS

INDUSTRY KEYWORD: BIOTECHNOLOGY GENERAL HEALTH HEALTH GENETICS ONCOLOGY

SOURCE: Castle Biosciences, Inc.

Copyright Business Wire 2019.

PUB: 11/20/2019 07:00 AM/DISC: 11/20/2019 07:01 AM

http://www.businesswire.com/news/home/20191120005028/en